Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Marksans PharmaBOM:524404 -0.10%85 PEG Ratio is 1.77 as of Jul. 26, 2026, which is 142% above its 10-year median of 0.73. GuruFocus rates BOM:524404 with a GF Score™ of 85/100 and a GF Value™ of ₹230.23 (Fairly Valued). The stock has 7 warning signs investors should review. Among 350 Drug Manufacturers companies, Marksans Pharma ranks worse than 50.86% on this metric.
* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
The historical rank and industry rank for Marksans Pharma's PEG Ratio or its related term are showing as below:
BOM:524404'
s PEG Ratio Range Over the Past 10 Years
Min: 0.15 Med: 0.73 Max: 19.46
Current: 1.77
During the past 13 years, Marksans Pharma's highest PEG Ratio was 19.46. The lowest was 0.15. And the median was 0.73.
BOM:524404's PEG Ratio is ranked worse than 50.86% of 350
companies
in the Drug Manufacturers industry
Industry Median: 1.71
vs BOM:524404: 1.77
Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.
Marksans Pharma (BOM:524404) PEG Ratio Explanation
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.
Marksans Pharma PEG Ratio Related Terms
Marksans Pharma PEG Ratio Historical Data
* Premium members only.
The historical data trend for Marksans Pharma's PEG Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:524404 vs LLY, JNJ, ABBV: PEG Ratio Comparison
For the Drug Manufacturers - General subindustry, Marksans Pharma's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Marksans Pharma PEG Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Marksans Pharma's PEG Ratio distribution charts can be found below:
* The bar in red indicates where Marksans Pharma's PEG Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
Marksans Pharma (BOM:524404) has a PEG Ratio of 1.77 as of Jul. 26, 2026. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Marksans Pharma and its competitors. This is 142% above median its historical median of 0.73. Over the past decade, Marksans Pharma's PEG Ratio has ranged from 0.15 to 19.46. According to the industry distribution chart, Marksans Pharma ranks #178 out of 350 companies in the Drug Manufacturers industry, placing it in the top 50.9%.
Is Marksans Pharma's PEG Ratio too high?
Marksans Pharma's current PEG Ratio of 1.77 is 142% above median its 10-year median of 0.73. Over the past 10 years, this metric has ranged from a low of 0.15 to a high of 19.46. The Drug Manufacturers industry median PEG Ratio is 1.71. Marksans Pharma's value of 1.77 is 3.5% above this industry median. Based on the distribution chart, Marksans Pharma ranks #178 out of 350 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Marksans Pharma has a GF Score™ of 85/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Marksans Pharma's PEG Ratio compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Marksans Pharma ranks #178 out of 350 companies for PEG Ratio. This places Marksans Pharma in the lower half of its industry. The industry median PEG Ratio is 1.71. Marksans Pharma's value of 1.77 is 3.5% above this benchmark. Historically, Marksans Pharma's own PEG Ratio has ranged from 0.15 to 19.46 over the past decade. While the company's 10-year median is 0.73 vs. the industry median of 1.71, Marksans Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PEG Ratio for a Drug Manufacturers company?
The median PEG Ratio among Drug Manufacturers companies is 1.71, based on 350 companies in the industry. Companies in the top quartile (top 25%) have a PEG Ratio significantly above this median, while those in the bottom quartile fall well below. However, PEG Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Marksans Pharma's current PEG Ratio of 1.77 is 3.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PEG Ratio mean?
A high PEG Ratio can signal that a stock is expensive relative to its fundamentals. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Marksans Pharma and its competitors. For the Drug Manufacturers industry, the median PEG Ratio is 1.71 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Marksans Pharma's current PEG Ratio is 1.77, which is 142% above median its own 10-year median of 0.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Marksans Pharma stock overvalued right now?
Based on GuruFocus' analysis, Marksans Pharma (BOM:524404) is currently considered Fairly Valued. The stock's GF Value™ is ₹230.23, compared to a current price of ₹246.25 — trading 7% above its estimated fair value. The current PEG Ratio is 1.77, which is 142% above median its 10-year median of 0.73 and 3.5% above the Drug Manufacturers industry median of 1.71. Marksans Pharma's overall GF Score™ is 85/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PEG Ratio calculated?
PEG Ratio is calculated from a company's financial statements. For Marksans Pharma (BOM:524404), the current PEG Ratio is 1.77 as of Jul. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Marksans Pharma (BOM:524404) Overvalued in 2026?
Based on GuruFocus' analysis, Marksans Pharma stock appears to be overvalued.
The current stock price of ₹246.25 is trading 7% above its estimated GF Value™ of ₹230.23.
GuruFocus considers Marksans Pharma to be Fairly Valued.
Key valuation signals for BOM:524404:
PEG Ratio: 1.77 (142% above median its 10-year median of 0.73)
GF Value™: ₹230.23 vs. price of ₹246.25 (7% above fair value)
Industry Position: 3.5% above the Drug Manufacturers median (#178 of 350)
No single metric tells the full story. See the BOM:524404 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Marksans Pharma Ltd is a pharmaceutical company. The company is engaged in the research, manufacturing, and marketing of pharmaceutical formulations. It manufactures analgesics, gastroenterology, anti-diabetic, cardiovascular, pain management, gynecology, gastrointestinal, and oncologic drugs as well as antibiotics and antiallergic medications. Geographically, the majority of its revenue is generated from the United States and North America, followed by Europe and the UK, Australia and New Zealand, and the Rest of the World.
85GF Score
Get the complete analysis for BOM:524404
PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:524404 has been successfully added to your 
